The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

Key Takeaways Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...

More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the ...

Scotiabank analyst Louise Chen maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

Oppenheimer analyst Andreas Argyrides lowered the firm’s price target on Sarepta (SRPT) to $184 from $215 and keeps an Outperform rating on the ...

LPL Financial LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 12.4% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 53,438 shares ...

In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other Wednesday’s top performers. The stock market regained momentum on Wednesday ...

A number of research firms recently commented on SRPT. Scotiabank lowered their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on ...